Free Trial

CVRx Q4 2024 Earnings Report

CVRx logo
$16.25 +0.79 (+5.11%)
As of 02/4/2025 04:00 PM Eastern

CVRx EPS Results

Actual EPS
-$0.43
Consensus EPS
-$0.37
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

CVRx Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CVRx Announcement Details

Quarter
Q4 2024
Time
After Market Closes

Conference Call Resources

CVRx Earnings Headlines

CVRx sees FY25 revenue $ $63M -$65M, consensus $64.16M
CVRx reports Q4 EPS (43c), consensus (38c)
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…
CVRx, Inc. (CVRX) Q4 2024 Earnings Conference Call Transcript
See More CVRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CVRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CVRx and other key companies, straight to your email.

About CVRx

CVRx (NASDAQ:CVRX), a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

View CVRx Profile

More Earnings Resources from MarketBeat